Vaccination against plague is an important element of control over this exceptionally virulent infection. To be effective against virulent Yersinia pestis strains live plague vaccine produced from Yersinia pestis EV strain (EV vaccine) requires annual revaccinations. Use of EV vaccine for revaccination is limited due to the initially developed immune response that suppresses the live vaccine culture. Earlier studies showed that the use of immunomodulators activates immune response to vaccination. In our study we assessed the influence of human recombinant interleukin-1beta (Betaleukin) on immunogenic and protective efficacy of live plague vaccine in controlled experiments on animal models (rabbits and guinea pigs). In a long experiment (261 days) on rabbits we assessed indicators of antigen specific immune response to F1 antigen of Yersinia pestis. The early antigen specific response was evaluated based on the appearance of different avidity lymphocytes with F1 receptors. Effector phase of the immune response was asses based on the activity of antigen-specific antibodies. Results showed that the use of betaleukin as an immunoadjuvant increases vaccination efficacy by strengthening the effector phase of the immune response and promotion of the early stage of antigen-specific immune response to EV vaccine. Protective efficacy of betaleukin and EV vaccine combination was assessed in an experiment with guinea pigs. This experiment showed that injections of betaleukin facilitates the production of antibodies following vaccination and significantly increases the rates of survival after the challenge with virulent plague strain. At the same time single injections of betaleukin alone did not protect guinea pigs from death after injections of virulent plague strains.

• MeSH
• adjuvancia imunologická MeSH
• antigeny povrchové imunologie   MeSH
• interleukin-1beta * aplikace a dávkování   imunologie   MeSH
• králíci MeSH
• modely u zvířat MeSH
• mor * imunologie   prevence a kontrola   MeSH
• morčata MeSH
• protilátky bakteriální imunologie   MeSH
• rekombinantní proteiny aplikace a dávkování   imunologie   MeSH
• vakcína proti moru * aplikace a dávkování   imunologie   MeSH
• vakcinace MeSH
• Yersinia pestis imunologie   MeSH
• zvířata MeSH
• Check Tag
• králíci MeSH
• morčata MeSH
• zvířata MeSH

The study was aimed at the experimental assessment of the efficacy of recombinant interleukin-1ß in the early therapy of haemopoiesis disorders caused by X-ray irradiation. The efficacy of the product was based on the 30-day survival rate and average life expectancy of dead animals. Endogenous and exogenous colony-formations were studied to reveal possible mechanisms of therapeutic effects of interleukin-1ß on the bone marrow. The early administration (10–15 min after exposure to radiation) of recombinant interleukin-1ß in a dose of 50 µg/kg increased the survival rate and prevented the post-irradiation decrease in the number of endogenous and exogenous CFU-S9 in irradiated mice.

• MeSH
• experimentální radiační poranění farmakoterapie   mortalita   MeSH
• hematopoéza účinky léků   účinky záření   MeSH
• interleukin-1beta aplikace a dávkování   MeSH
• krevní nemoci etiologie   farmakoterapie   krev   mortalita   MeSH
• míra přežití MeSH
• myši inbrední C57BL MeSH
• myši inbrední CBA MeSH
• myši MeSH
• radioprotektivní látky terapeutické užití   MeSH
• rekombinantní proteiny aplikace a dávkování   MeSH
• zvířata MeSH
• Check Tag
• mužské pohlaví MeSH
• myši MeSH
• zvířata MeSH